The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic

Makvandi, Mehran; Lieberman, Brian P.; LeGeyt, Ben; Hou, Catherine; Mankoff, David A.; Mach, Robert H.; Pryma, Daniel A.

doi:10.1016/j.nucmedbio.2015.10.001

Title: The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic

Full Record
Other Related Research

Authors:: Makvandi, Mehran; Lieberman, Brian P.; LeGeyt, Ben; Hou, Catherine; Mankoff, David A.; Mach, Robert H.; Pryma, Daniel A.

Publication Date:: Fri Jan 01 00:00:00 EST 2016

Sponsoring Org.:: USDOE

OSTI Identifier:: 1556171

Grant/Contract Number:: FOA-0001075

Resource Type:: Publisher's Accepted Manuscript

Journal Name:: Nuclear Medicine and Biology

Additional Journal Information:: Journal Name: Nuclear Medicine and Biology Journal Volume: 43 Journal Issue: 1; Journal ID: ISSN 0969-8051

Publisher:: Elsevier

Country of Publication:: United Kingdom

Language:: English

Citation Formats


                    Makvandi, Mehran, Lieberman, Brian P., LeGeyt, Ben, Hou, Catherine, Mankoff, David A., Mach, Robert H., and Pryma, Daniel A. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.  United Kingdom: N. p., 2016. 
Web.  doi:10.1016/j.nucmedbio.2015.10.001.

Copy to clipboard


                    Makvandi, Mehran, Lieberman, Brian P., LeGeyt, Ben, Hou, Catherine, Mankoff, David A., Mach, Robert H., & Pryma, Daniel A. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.  United Kingdom.  https://doi.org/10.1016/j.nucmedbio.2015.10.001

Copy to clipboard


                    Makvandi, Mehran, Lieberman, Brian P., LeGeyt, Ben, Hou, Catherine, Mankoff, David A., Mach, Robert H., and Pryma, Daniel A. Fri .  
"The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic".  United Kingdom.  https://doi.org/10.1016/j.nucmedbio.2015.10.001.

Copy to clipboard


                    
@article{osti_1556171,

  title        = {The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic},

  author       = {Makvandi, Mehran and Lieberman, Brian P. and LeGeyt, Ben and Hou, Catherine and Mankoff, David A. and Mach, Robert H. and Pryma, Daniel A.},

  abstractNote = {},

  doi          = {10.1016/j.nucmedbio.2015.10.001},

  journal      = {Nuclear Medicine and Biology},

  number       = 1,

  volume       = 43,

  place        = {United Kingdom},

  year         = {Fri Jan 01 00:00:00 EST 2016},

  month        = {Fri Jan 01 00:00:00 EST 2016}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Publisher's Version of Record
https://doi.org/10.1016/j.nucmedbio.2015.10.001

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 17 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Engineered Modular Recombinant Transporters: Application of New Platform for Targeted Radiotherapeutic Agents to {alpha}-Particle Emitting {sup 211}At

Journal Article Rosenkranz, Andrey A ; Department of Biophysics, Biological Faculty, Moscow State University, Moscow ; Vaidyanathan, Ganesan ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To generate and evaluate a modular recombinant transporter (MRT) for targeting {sup 211}At to cancer cells overexpressing the epidermal growth factor receptor (EGFR). Methods and Materials: The MRT was produced with four functional modules: (1) human epidermal growth factor as the internalizable ligand, (2) the optimized nuclear localization sequence of simian vacuolating virus 40 (SV40) large T-antigen, (3) a translocation domain of diphtheria toxin as an endosomolytic module, and (4) the Escherichia coli hemoglobin-like protein (HMP) as a carrier module. MRT was labeled using N-succinimidyl 3-[{sup 211}At]astato-5-guanidinomethylbenzoate (SAGMB), its {sup 125}I analogue SGMIB, or with {sup 131}I using Iodogen.more »« less
https://doi.org/10.1016/j.ijrobp.2008.05.055
Synthesis and evaluation of 2-halogenated-1,1-bis(4-hydroxyphenyl)-2-(3-hydroxyphenyl)-ethylenes as potential estrogen receptor-targeted radiodiagnostic and radiotherapeutic agents

Journal Article Hanson, Robert N. ; Tongcharoensirikul, Pakamas ; Barnsley, Kelly ; ... - Steroids
Cited by 2
https://doi.org/10.1016/j.steroids.2015.01.013
Improved safety and efficacy of ²¹³Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Journal Article Chan, Ho Sze ; Konijnenberg, Mark W. ; Daniels, Tamara ; ... - EJNMMI Research

Background: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with ¹⁷⁷Lu-DOTATATE or ⁹⁰Y-DOTATOC has shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the proximal tubules, thereby enabling higher radioactivity to be safely administered. The aim of this preclinical study was to evaluate the therapeutic effect of ²¹³Bi-DOTATATE with and without renal protection using L-lysine in mice. Tumor uptake and kinetics as a function of injected mass of peptide (rangemore »« less
Cited by 35
https://doi.org/10.1186/s13550-016-0240-5

Full Text Available
Expansion of the. alpha. sub 2 -adrenergic receptor family: Cloning and characterization of a human. alpha. sub 2 -adrenergic receptor subtype, the gene for which is located on chromosome 2

Journal Article Lomasney, J W ; Lorenz, W ; Allen, L F ; ... - Proceedings of the National Academy of Sciences of the United States of America; (USA)

Pharmacologic, biochemical, and genetic analyses have demonstrated the existence of multiple {alpha}{sub 2}-adrenergic receptor ({alpha}{sub 2}AR) subtypes. The authors have cloned a human {alpha}{sub 2}AR by using the polymerase chain reaction with oligonucleotide primers homologous to conserved regions of the previously cloned {alpha}{sub 2}ARs, the genes for which are located on human chromosomes 4 (C4) and 10 (C10). The deduced amino acid sequence encodes a protein of 450 amino acids whose putative topology is similar to that of the family of guanine nucleotide-binding protein-coupled receptors, but whose structure most closely resembles that of the {alpha}{sub 2}ARs. Competition curve analysis ofmore »« less
https://doi.org/10.1073/pnas.87.13.5094
The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer

Journal Article Makvandi, Mehran ; Tilahun, Estifanos D. ; Lieberman, Brian P. ; ... - Biochemical and Biophysical Research Communications

Background: Triple-negative breast cancer (TNBC) is associated with high relapse rates and increased mortality when compared with other breast cancer subtypes. In contrast to receptor positive breast cancers, there are no approved targeted therapies for TNBC. Identifying biomarkers for TNBC is of high importance for the advancement of patient care. The sigma-2 receptor has been shown to be overexpressed in triple negative breast cancer in vivo and has been characterized as a marker of proliferation. The aim of the present study was to define the sigma-2 receptor as a target for therapeutic drug delivery and biomarker in TNBC. Methods: Three TNBCmore »« less
https://doi.org/10.1016/J.BBRC.2015.09.157

Similar Records